Contact
searchSearch
HMP Global
Login

Alzheimer & Dementia Related Cognitive Disorders Topic Center

A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
Meagan Thistle
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Brionna Mendoza
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
a researcher examines MRI scans
News
Diabetes, Amyloid Pathology Linked With Progression to MCI Over 20 Years
01/02/2025
Jolynn Tumolo
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal...
01/02/2025
Neurology
From Neurology
Regular Physical Activity After Dementia Diagnosis May Lower Mortality Risk
News
Regular Physical Activity After Dementia Diagnosis May Lower Mortality Risk
11/21/2024
Evi Arthur
Regular physical activity (PA) following dementia diagnosis could lower the risk of all-cause mortality, according to results from a retrospective cohort study published in the British Journal of Sports Medicine.
Regular physical activity (PA) following dementia diagnosis could lower the risk of all-cause mortality, according to results from a retrospective cohort study published in the British Journal of Sports Medicine.
Regular physical activity (PA)...
11/21/2024
Psych Congress Network
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Jolynn Tumolo
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
An elderly woman sits on a couch
News
Increasing Depression Symptoms in Older Adults Associated With Amyloid Accumulation
09/09/2024
Brionna Mendoza
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms...
09/09/2024
Psych Congress Network
an older adult lies in a hospital bed with head turned looking out of a window
News
Suvorexant Associated With Lower Delirium Rates in Some Hospitalized Older Adults
08/29/2024
Jolynn Tumolo
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting...
08/29/2024
Psych Congress Network
Collaborative Dementia Care Tied with Improved Outcomes
News
Collaborative Dementia Care Tied With Improved Outcomes
08/14/2024
Evi Arthur
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care...
08/14/2024
Neurology
From Neurology
marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
Marc E. Agronin, MD
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network

News

A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
Meagan Thistle
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Brionna Mendoza
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
a researcher examines MRI scans
News
Diabetes, Amyloid Pathology Linked With Progression to MCI Over 20 Years
01/02/2025
Jolynn Tumolo
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal...
01/02/2025
Neurology
Regular Physical Activity After Dementia Diagnosis May Lower Mortality Risk
News
Regular Physical Activity After Dementia Diagnosis May Lower Mortality Risk
11/21/2024
Evi Arthur
Regular physical activity (PA) following dementia diagnosis could lower the risk of all-cause mortality, according to results from a retrospective cohort study published in the British Journal of Sports Medicine.
Regular physical activity (PA) following dementia diagnosis could lower the risk of all-cause mortality, according to results from a retrospective cohort study published in the British Journal of Sports Medicine.
Regular physical activity (PA)...
11/21/2024
Psych Congress Network
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Jolynn Tumolo
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
An elderly woman sits on a couch
News
Increasing Depression Symptoms in Older Adults Associated With Amyloid Accumulation
09/09/2024
Brionna Mendoza
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms...
09/09/2024
Psych Congress Network
an older adult lies in a hospital bed with head turned looking out of a window
News
Suvorexant Associated With Lower Delirium Rates in Some Hospitalized Older Adults
08/29/2024
Jolynn Tumolo
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting...
08/29/2024
Psych Congress Network
Collaborative Dementia Care Tied with Improved Outcomes
News
Collaborative Dementia Care Tied With Improved Outcomes
08/14/2024
Evi Arthur
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care...
08/14/2024
Neurology
Alzheimer and cognitive decline graphic
News
Novel AD Treatment Approach Shows Promise in First Human Trial
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a...
06/25/2024
Psych Congress Network
Study on MDD - stock image
News
Phase II Trial of AL001 for MDD Set to Begin Later this Year
03/24/2025
Jolynn Tumolo
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a...
03/24/2025
Psych Congress Network
US FDA sign
News
FDA Seeks Clearer Labeling for Transmucosal Buprenorphine Product Dosing
03/24/2025
Jolynn Tumolo
To avoid misperceptions that current labeling for buprenorphine-containing transmucosal products includes a maximum daily dose, the US Food and Drug Administration (FDA) is encouraging the submission of supplemental new drug applications to...
To avoid misperceptions that current labeling for buprenorphine-containing transmucosal products includes a maximum daily dose, the US Food and Drug Administration (FDA) is encouraging the submission of supplemental new drug applications to...
To avoid misperceptions that...
03/24/2025
Psych Congress Network
3 medical professionals stand together talking in the hallway of a medical facility
News
Accelerated Theta-Burst Stimulation Protocol Improves Treatment-Resistant Depression
03/21/2025
Jolynn Tumolo
A novel 78-minute accelerated theta-burst stimulation (aTBS) protocol reduced depression severity in patients with treatment-resistant depression (TRD), according to results from a randomized clinical trial published in JAMA Psychiatry.
A novel 78-minute accelerated theta-burst stimulation (aTBS) protocol reduced depression severity in patients with treatment-resistant depression (TRD), according to results from a randomized clinical trial published in JAMA Psychiatry.
A novel 78-minute accelerated...
03/21/2025
Psych Congress Network
an older man wearing glasses rubs his face in stress tired depression treatment resistant depression
News
Genetic Predispositions to Insomnia, Neuroticism, Linked With Higher Risk for Treatment-Resistant Depression
03/18/2025
Jolynn Tumolo
A genetic predisposition to traits including neuroticism, cognitive function, and sleep patterns were significantly associated with the development of treatment-resistant depression (TRD) in a cohort study published in JAMA Psychiatry.
A genetic predisposition to traits including neuroticism, cognitive function, and sleep patterns were significantly associated with the development of treatment-resistant depression (TRD) in a cohort study published in JAMA Psychiatry.
A genetic predisposition to...
03/18/2025
Psych Congress Network
Woman sitting at bar holding a drink.
News
Semaglutide Reduces Cravings in Adults with Alcohol Use Disorder
03/13/2025
Jolynn Tumolo
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose...
03/13/2025
Psych Congress Network
emergency room hospital waiting room reception area
News
Why Aren’t More Emergency Departments Using Medications for OUD Treatment?
03/12/2025
Jolynn Tumolo
Barriers may be hampering the use of medications for opioid use disorder (MOUD) in US emergency departments (EDs), according to results from a systematic review published in the Journal of Substance Use & Addiction Treatment.
Barriers may be hampering the use of medications for opioid use disorder (MOUD) in US emergency departments (EDs), according to results from a systematic review published in the Journal of Substance Use & Addiction Treatment.
Barriers may be hampering the...
03/12/2025
Psych Congress Network
stethoscope with research images in background medical study clinical trial research
News
Machine Learning Predicts Progression to Schizophrenia Within 5 Years
03/12/2025
Jolynn Tumolo
Machine learning models used routine clinical data from electronic health records to predict progression to schizophrenia and bipolar disorder within 5 years for patients with pre-existing mental illness, according to a study published in...
Machine learning models used routine clinical data from electronic health records to predict progression to schizophrenia and bipolar disorder within 5 years for patients with pre-existing mental illness, according to a study published in...
Machine learning models used...
03/12/2025
Psych Congress Network
two researchers look at computer screen in lab medical research
News
Continuous D2 Blockade in First-Episode Schizophrenia Does Not Raise Relapse Risk
03/05/2025
Jolynn Tumolo
More than 5 years of continuous treatment with dopamine D2 receptor-blocking long-acting injectable (LAI) antipsychotics does not appear to increase the risk of breakthrough psychosis in patients with first-episode schizophrenia.
More than 5 years of continuous treatment with dopamine D2 receptor-blocking long-acting injectable (LAI) antipsychotics does not appear to increase the risk of breakthrough psychosis in patients with first-episode schizophrenia.
More than 5 years of continuous...
03/05/2025
Psych Congress Network
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
A woman lies on the couch holding an ice pack to her head
News
Mild TBI Sustained in Traumatic Context Associated With Worse Long-Term Outcomes
03/03/2025
Jolynn Tumolo
Mild traumatic brain injury (mTBI) that occurred in the context of psychological trauma was associated with poorer long-term outcomes, including greater posttraumatic stress disorder (PTSD) severity, postconcussive symptoms, and disability.
Mild traumatic brain injury (mTBI) that occurred in the context of psychological trauma was associated with poorer long-term outcomes, including greater posttraumatic stress disorder (PTSD) severity, postconcussive symptoms, and disability.
Mild traumatic brain injury...
03/03/2025
Neurology

Quizzes

quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
Why do hurricanes increase mortality risk in ADRD populations?
Quiz
Why do hurricanes increase mortality risk in ADRD populations?
04/04/2023
Do you remember this study?
Do you remember this study?
Do you remember this study?
04/04/2023
Psych Congress Network
Four pencils with their erasers spelling out "quiz."
Quiz
What strategies can individuals use to reduce their risk of Alzheimer disease?
09/28/2022
Take the quiz to test your clinical knowledge!
Take the quiz to test your clinical knowledge!
Take the quiz to test your...
09/28/2022
Psych Congress Network
Dr Steven Chan
Expert Insights Quiz
Choosing the Right Digital Therapeutic for MDD Treatment
03/18/2025
Steven Chan, MD, MBA; Meagan Thistle
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress...
03/18/2025
Psych Congress Network
Did OUD diagnoses increase or decrease in VHA patients?
Quiz
Did OUD diagnoses increase or decrease in VHA patients?
02/25/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/25/2025
Psych Congress Network
Charles Raison headshot
Expert Insights Quiz
First-Line Treatment Options for Insomnia
02/21/2025
Charles L. Raison, MD
True or False: According to Psych Congress Steering Committee Member, Charles Raison, MD, the first-line treatment for primary insomnia is medication, including benzodiazepines.
True or False: According to Psych Congress Steering Committee Member, Charles Raison, MD, the first-line treatment for primary insomnia is medication, including benzodiazepines.
True or False: According to...
02/21/2025
Psych Congress Network
Quiz
Quiz
Cariprazine FDA-Approved Indications
02/21/2025
Meagan Thistle
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as...
02/21/2025
Psych Congress Network
How many US Psychiatric Hospitals Provided Medications for OUD?
Quiz
How many US psychiatric hospitals provided medications for OUD?
02/06/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/06/2025
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
DSM-5 Quiz: Mood Symptoms in Schizophrenia
02/03/2025
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
02/03/2025
Psych Congress Network
How many people with anxiety disorders receive treatment?
Quiz
How many people with anxiety disorders receive treatment?
01/28/2025
Test your statistical knowledge!
Test your statistical knowledge!
Test your statistical knowledge!
01/28/2025
Psych Congress Network
How can clinicians help patients with ADHD transition from adolescence to adulthood?
Quiz
How can clinicians help patients with ADHD transition from adolescence to adulthood?
01/22/2025
Do you remember this interview with Dr Wilens?
Do you remember this interview with Dr Wilens?
Do you remember this interview...
01/22/2025
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
Quiz
Conditions That Mimic ADHD in Pediatric Patients
01/21/2025
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
01/21/2025
Psych Congress Network
Quiz
Quiz
What percentage of people experience hypomanic symptoms during an MDD episode?
01/15/2025
Meagan Thistle
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network

Perspectives

marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
Marc E. Agronin, MD
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Leslie Citrome, MD, MPH.
Videos
Addressing Agitation in Dementia
11/09/2023
Leslie Citrome, MD
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals...
11/09/2023
Psychiatry & Behavioral Health
Dr Paul Schulz
Videos
Lecanemab Considerations and Efficacy
10/16/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
10/16/2023
Psych Congress Network
Dr Paul Schulz
Videos
Patient Considerations When Prescribing Lecanemab for Alzheimer Disease
09/22/2023
Paul Schulz, MD
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
09/22/2023
Psych Congress Network
Dr Paul Schulz
Videos
Advantages and Drawbacks of Lecanemab in Alzheimer Disease Treatment
09/11/2023
Paul Schulz, MD
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the...
09/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
Telepsychiatry Practice for Geriatric Patients
08/11/2023
Marc E. Agronin, MD
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych...
08/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
What the Data Tells Us About Telepsychiatry Efficacy and Popularity
07/20/2023
Marc E. Agronin, MD
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric...
07/20/2023
Psych Congress Network
Marc Agronin, MD.
Blog
Alzheimer Disease Prevention
08/30/2022
Marc E. Agronin, MD
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Douglas_Scharre_alzheimers_aducanumab
Videos
Putting Research Into Practice With Aducanumab for Alzheimer Disease
08/27/2021
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre,...
08/27/2021
Psych Congress Network
Improving Cognition in Patients With Alzheimer’s Disease
Videos
Improving Cognition in Patients With Alzheimer’s Disease
11/11/2020
In this video, geriatric psychiatrist Marc E. Agronin, MD, discusses medications that may improve cognition in patients with Alzheimer's disease.
In this video, geriatric psychiatrist Marc E. Agronin, MD, discusses medications that may improve cognition in patients with Alzheimer's disease.
In this video, geriatric...
11/11/2020
Psych Congress Network
Thomas L. Schwartz, MD
Q&As
A Psychiatrist’s Role in Tackling Sleep-Wake Disorders
03/18/2025
Thomas L. Schwartz, MD, explores medicine’s evolving understanding of insomnia, narcolepsy, and idiopathic hypersomnia from a neuroscientific perspective.
Thomas L. Schwartz, MD, explores medicine’s evolving understanding of insomnia, narcolepsy, and idiopathic hypersomnia from a neuroscientific perspective.
Thomas L. Schwartz, MD, explores...
03/18/2025
Psych Congress Network
Brittany Albright
Q&As
Evaluating Anhedonia With Patient-Centered Strategies
03/11/2025
In part 2 of this Q and A, Brittany Albright, MD, MPH, Psych Congress Elevate faculty member and founder of Sweetgrass Psychiatry, discusses 2 of her favorite anhedonia treatment strategies.
In part 2 of this Q and A, Brittany Albright, MD, MPH, Psych Congress Elevate faculty member and founder of Sweetgrass Psychiatry, discusses 2 of her favorite anhedonia treatment strategies.
In part 2 of this Q and...
03/11/2025
Psych Congress Network
Dr Brittany Albright
Q&As
Exploring Anhedonia in Psychiatric Care
03/04/2025
In this Q&A, Psych Congress Elevate faculty member Dr Brittany Albright discusses the challenging symptoms of anhedonia and its significant impact on patients' quality of life and clinical outcomes.
In this Q&A, Psych Congress Elevate faculty member Dr Brittany Albright discusses the challenging symptoms of anhedonia and its significant impact on patients' quality of life and clinical outcomes.
In this Q&A, Psych Congress...
03/04/2025
Psych Congress Network
Examining Novel Treatment Methods in Schizophrenia
Videos
Examining Novel Treatment Methods in Schizophrenia
02/25/2025
Christoph U. Correll, MD
In this discussion, Christoph Correll, MD, professor of psychiatry at the Zucker School of Medicine, delves into the groundbreaking FDA approval of xanomeline/tropsium chloride, a novel treatment for schizophrenia that moves beyond...
In this discussion, Christoph Correll, MD, professor of psychiatry at the Zucker School of Medicine, delves into the groundbreaking FDA approval of xanomeline/tropsium chloride, a novel treatment for schizophrenia that moves beyond...
In this discussion, Christoph...
02/25/2025
Psych Congress Network
Steven Chan, MD, MBA, FAPA, FAMIA
Videos
Barriers and Misconceptions to Digital Therapeutic Integration
02/14/2025
Steven Chan, MD, MBA
In this video, Steven Chan, MD, MBA, FAPA, FAMIA, Psych Congress Steering Committee, explains some of the barriers that virtual clinicians should anticipate when weighing digital therapeutic options for major depressive disorder (MDD)...
In this video, Steven Chan, MD, MBA, FAPA, FAMIA, Psych Congress Steering Committee, explains some of the barriers that virtual clinicians should anticipate when weighing digital therapeutic options for major depressive disorder (MDD)...
In this video, Steven Chan, MD,...
02/14/2025
Psych Congress Network
Steven Chan, MD, MBA, FAPA, FAMIA
Videos
Tapping into Neuroplasticity Through Digital Therapeutics for MDD
02/10/2025
Steven Chan, MD, MBA
Steven Chan, MD, MBA, FAPA, FAMIA, explains how telehealth providers can explore and adopt digital therapeutics for their virtual practices.
Steven Chan, MD, MBA, FAPA, FAMIA, explains how telehealth providers can explore and adopt digital therapeutics for their virtual practices.
Steven Chan, MD, MBA, FAPA,...
02/10/2025
Psych Congress Network
Brooke Kempf, PMHNP-BC
Videos
Improving Patient Outcomes With Early Initiation of LAIs
02/05/2025
Brooke Kempf, MSN, PMHNP-BC
What role do long-acting injectables (LAIs) play in improving long-term outcomes for patients with schizophrenia? In this discussion, Brooke Kempf, PMHNP-BC, highlights the benefits of early LAI initiation, from reducing relapse rates and...
What role do long-acting injectables (LAIs) play in improving long-term outcomes for patients with schizophrenia? In this discussion, Brooke Kempf, PMHNP-BC, highlights the benefits of early LAI initiation, from reducing relapse rates and...
What role do long-acting...
02/05/2025
Psych Congress Network
Edward Kaftarian, MD.
Videos
Treating Substance Use Disorder via Telehealth
01/30/2025
Edward Kaftarian, MD
Edward Kaftarian, MD, shares his insights on the clinical, legal, and technological factors that impact virtual care for SUD.
Edward Kaftarian, MD, shares his insights on the clinical, legal, and technological factors that impact virtual care for SUD.
Edward Kaftarian, MD, shares...
01/30/2025
Psych Congress Network
Brooke Kempf
Videos
Addressing Misconceptions About LAI Antipsychotics
01/06/2025
Brooke Kempf, MSN, PMHNP-BC
Kempf emphasizes the power of patient education, addressing myths, and involving families to ease the daily medication burden. 
Kempf emphasizes the power of patient education, addressing myths, and involving families to ease the daily medication burden. 
Kempf emphasizes the power of...
01/06/2025
Psych Congress Network
Desiree Matthews, PMHNP-BC, CEO
Videos
How to Navigate Insurance When Treating Tardive Dyskinesia
01/06/2025
Desiree Matthews, PHMNP-BC
In this video, Desiree Matthews, PMHNP-BC, discusses how to navigate insurance policies when treating tardive dyskinesia.
In this video, Desiree Matthews, PMHNP-BC, discusses how to navigate insurance policies when treating tardive dyskinesia.
In this video, Desiree Matthews,...
01/06/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use